{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:15Z","timestamp":1793321775311,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12020-019-02034-4","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T11:19:50Z","timestamp":1564744790000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["High bone marrow fat in patients with Cushing\u2019s syndrome and vertebral fractures"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7472-6598","authenticated-orcid":false,"given":"Francesco","family":"Ferra\u00f9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Giovinazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Tessitore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gherardo","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"2034_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"R. Pivonello, A.M. Isidori, M.C. De Martino, J. Newell-Price, B.M. Biller, A. Colao, Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol. 4, 611\u2013629 (2016). \nhttps:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2034_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000486002","volume":"49","author":"F Ferrau","year":"2018","unstructured":"F. Ferrau, M. Korbonits, Metabolic syndrome in Cushing\u2019s syndrome patients. Front. Horm. Res. 49, 85\u2013103 (2018). \nhttps:\/\/doi.org\/10.1159\/000486002","journal-title":"Front. Horm. Res."},{"key":"2034_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/HJH.0000000000000415","volume":"33","author":"AM Isidori","year":"2015","unstructured":"A.M. Isidori, C. Graziadio, R.M. Paragliola, A. Cozzolino, A.G. Ambrogio, A. Colao, S.M. Corsello, R. Pivonello, A.B.C.S. Group, The hypertension of Cushing\u2019s syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J. Hypertens. 33, 44\u201360 (2015). \nhttps:\/\/doi.org\/10.1097\/HJH.0000000000000415","journal-title":"J. Hypertens."},{"key":"2034_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319\u20131328 (2007). \nhttps:\/\/doi.org\/10.1007\/s00198-007-0394-0","journal-title":"Osteoporos. Int."},{"key":"2034_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000443866","volume":"46","author":"G Mazziotti","year":"2016","unstructured":"G. Mazziotti, A. Delgado, F. Maffezzoni, A. Formenti, A. Giustina, Skeletal fragility in endogenous hypercortisolism. Front. Horm. Res. 46, 66\u201373 (2016). \nhttps:\/\/doi.org\/10.1159\/000443866","journal-title":"Front. Horm. Res."},{"key":"2034_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00198-013-2588-y","volume":"25","author":"A Scillitani","year":"2014","unstructured":"A. Scillitani, G. Mazziotti, C. Di Somma, S. Moretti, A. Stigliano, R. Pivonello, A. Giustina, A. Colao, Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos. Int. 25, 441\u2013446 (2014). \nhttps:\/\/doi.org\/10.1007\/s00198-013-2588-y","journal-title":"Osteoporos. Int."},{"key":"2034_CR7","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1210\/jc.2005-0582","volume":"91","author":"L Tauchmanova","year":"2006","unstructured":"L. Tauchmanova, R. Pivonello, C. Di Somma, R. Rossi, M.C. De Martino, L. Camera, M. Klain, M. Salvatore, G. Lombardi, A. Colao, Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J. Clin. Endocrinol. Metab. 91, 1779\u20131784 (2006). \nhttps:\/\/doi.org\/10.1210\/jc.2005-0582","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2034_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","volume":"16","author":"John T. Schousboe","year":"2013","unstructured":"Schousboe, J.T., Shepherd, J.A., Bilezikian, J.P., Baim, S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J. Clin. Densitom. 16, 455\u2013466 (2013). \nhttps:\/\/doi.org\/10.1016\/j.jocd.2013.08.004","journal-title":"Journal of Clinical Densitometry"},{"key":"2034_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","volume":"41","author":"G Mazziotti","year":"2012","unstructured":"G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58\u201369 (2012). \nhttps:\/\/doi.org\/10.1007\/s12020-011-9570-2","journal-title":"Endocrine"},{"key":"2034_CR10","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00198-013-2520-5","volume":"25","author":"L Trementino","year":"2014","unstructured":"L. Trementino, G. Appolloni, L. Ceccoli, G. Marcelli, C. Concettoni, M. Boscaro, G. Arnaldi, Bone complications in patients with Cushing\u2019s syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporos. Int. 25, 913\u2013921 (2014). \nhttps:\/\/doi.org\/10.1007\/s00198-013-2520-5","journal-title":"Osteoporos. Int."},{"key":"2034_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/eje-11-0272","volume":"165","author":"E Valassi","year":"2011","unstructured":"E. Valassi, A. Santos, M. Yaneva, M. Toth, C.J. Strasburger, P. Chanson, J.A. Wass, O. Chabre, M. Pfeifer, R.A. Feelders, S. Tsagarakis, P.J. Trainer, H. Franz, K. Zopf, S. Zacharieva, S.W. Lamberts, A. Tabarin, S.M. Webb, The European Registry on Cushing\u2019s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur. J. Endocrinol. 165, 383\u2013392 (2011). \nhttps:\/\/doi.org\/10.1530\/eje-11-0272","journal-title":"Eur. J. Endocrinol."},{"key":"2034_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-015-0244-1","volume":"10","author":"ZE Belaya","year":"2015","unstructured":"Z.E. Belaya, D. Hans, L.Y. Rozhinskaya, N.V. Dragunova, N.I. Sasonova, A.G. Solodovnikov, T.T. Tsoriev, L.K. Dzeranova, G.A. Melnichenko, I.I. Dedov, The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing\u2019s syndrome. Arch. Osteoporos. 10, 44 (2015). \nhttps:\/\/doi.org\/10.1007\/s11657-015-0244-1","journal-title":"Arch. Osteoporos."},{"key":"2034_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.tem.2006.03.009","volume":"17","author":"G Mazziotti","year":"2006","unstructured":"G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144\u2013149 (2006). \nhttps:\/\/doi.org\/10.1016\/j.tem.2006.03.009","journal-title":"Trends Endocrinol. Metab."},{"key":"2034_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s001980170115","volume":"12","author":"H Tsugeno","year":"2001","unstructured":"H. Tsugeno, B. Goto, T. Fujita, M. Okamoto, T. Mifune, F. Mitsunobu, K. Ashida, Y. Hosaki, T. Tsuji, Y. Tanizaki, Oral glucocorticoid-induced fall in cortical bone volume and density in postmenopausal asthmatic patients. Osteoporos. Int. 12, 266\u2013270 (2001). \nhttps:\/\/doi.org\/10.1007\/s001980170115","journal-title":"Osteoporos. Int."},{"key":"2034_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1359\/jbmr.2001.16.1.97","volume":"16","author":"L Dalle Carbonare","year":"2001","unstructured":"L. Dalle Carbonare, M.E. Arlot, P.M. Chavassieux, J.P. Roux, N.R. Portero, P.J. Meunier, Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J. Bone Miner. Res. 16, 97\u2013103 (2001). \nhttps:\/\/doi.org\/10.1359\/jbmr.2001.16.1.97","journal-title":"J. Bone Miner. Res."},{"key":"2034_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/cen.12812","volume":"83","author":"CV dos Santos","year":"2015","unstructured":"C.V. dos Santos, L. Vieira Neto, M. Madeira, M.C. Alves Coelho, L.M. de Mendonca, P. Paranhos-Neto Fde, I.C. Lima, M.R. Gadelha, M.L. Farias, Bone density and microarchitecture in endogenous hypercortisolism. Clin. Endocrinol. 83, 468\u2013474 (2015). \nhttps:\/\/doi.org\/10.1111\/cen.12812","journal-title":"Clin. Endocrinol."},{"key":"2034_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/er.2018-00005","volume":"39","author":"G Mazziotti","year":"2018","unstructured":"G. Mazziotti, S. Frara, A. Giustina, Pituitary diseases and bone. Endocr. Rev. 39, 440\u2013488 (2018). \nhttps:\/\/doi.org\/10.1210\/er.2018-00005","journal-title":"Endocr. Rev."},{"key":"2034_CR18","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/jbmr.1648","volume":"27","author":"C Eller-Vainicher","year":"2012","unstructured":"C. Eller-Vainicher, V. Morelli, F.M. Ulivieri, S. Palmieri, V.V. Zhukouskaya, E. Cairoli, R. Pino, A. Naccarato, A. Scillitani, P. Beck-Peccoz, I. Chiodini, Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism. J. Bone Miner. Res. 27, 2223\u20132230 (2012). \nhttps:\/\/doi.org\/10.1002\/jbmr.1648","journal-title":"J. Bone Miner. Res."},{"key":"2034_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i2.20","volume":"19","author":"CJ Rosen","year":"2009","unstructured":"C.J. Rosen, C. Ackert-Bicknell, J.P. Rodriguez, A.M. Pino, Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit. Rev. Eukaryot. Gene Expr. 19, 109\u2013124 (2009)","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"2034_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1474-9728.2004.00127.x","volume":"3","author":"EJ Moerman","year":"2004","unstructured":"E.J. Moerman, K. Teng, D.A. Lipschitz, B. Lecka-Czernik, Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma\/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta\/BMP signaling pathways. Aging Cell 3, 379\u2013389 (2004). \nhttps:\/\/doi.org\/10.1111\/j.1474-9728.2004.00127.x","journal-title":"Aging Cell"},{"key":"2034_CR21","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1148\/radiology.217.2.r00nv20527","volume":"217","author":"FW Wehrli","year":"2000","unstructured":"F.W. Wehrli, J.A. Hopkins, S.N. Hwang, H.K. Song, P.J. Snyder, J.G. Haddad, Cross-sectional study of osteopenia with quantitative MR imaging and bone densitometry. Radiology 217, 527\u2013538 (2000). \nhttps:\/\/doi.org\/10.1148\/radiology.217.2.r00nv20527","journal-title":"Radiology"},{"key":"2034_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1023\/A:1011513223894","volume":"2","author":"J Justesen","year":"2001","unstructured":"J. Justesen, K. Stenderup, E.N. Ebbesen, L. Mosekilde, T. Steiniche, M. Kassem, Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2, 165\u2013171 (2001)","journal-title":"Biogerontology"},{"key":"2034_CR23","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1210\/jc.2012-3949","volume":"98","author":"AV Schwartz","year":"2013","unstructured":"A.V. Schwartz, S. Sigurdsson, T.F. Hue, T.F. Lang, T.B. Harris, C.J. Rosen, E. Vittinghoff, K. Siggeirsdottir, G. Sigurdsson, D. Oskarsdottir, K. Shet, L. Palermo, V. Gudnason, X. Li, Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. J. Clin. Endocrinol. Metab. 98, 2294\u20132300 (2013). \nhttps:\/\/doi.org\/10.1210\/jc.2012-3949","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2034_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1148\/radiol.2363041425","volume":"236","author":"JF Griffith","year":"2005","unstructured":"J.F. Griffith, D.K. Yeung, G.E. Antonio, F.K. Lee, A.W. Hong, S.Y. Wong, E.M. Lau, P.C. Leung, Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology 236, 945\u2013951 (2005). \nhttps:\/\/doi.org\/10.1148\/radiol.2363041425","journal-title":"Radiology"},{"key":"2034_CR25","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1210\/jc.2011-3123","volume":"97","author":"EB Geer","year":"2012","unstructured":"E.B. Geer, W. Shen, E. Strohmayer, K.D. Post, P.U. Freda, Body composition and cardiovascular risk markers after remission of Cushing\u2019s disease: a prospective study using whole-body MRI. J. Clin. Endocrinol. Metab. 97, 1702\u20131711 (2012). \nhttps:\/\/doi.org\/10.1210\/jc.2011-3123","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2034_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1530\/eje-18-0318","volume":"179","author":"F Maurice","year":"2018","unstructured":"F. Maurice, A. Dutour, C. Vincentelli, I. Abdesselam, M. Bernard, H. Dufour, Y. Le Fur, T. Graillon, F. Kober, P. Cristofari, E. Jouve, L. Pini, R. Fernandez, C. Chagnaud, T. Brue, F. Castinetti, B. Gaborit, Active cushing syndrome patients have increased ectopic fat deposition and bone marrow fat content compared to cured patients and healthy subjects: a pilot 1H-MRS study. Eur. J. Endocrinol. 179, 307\u2013317 (2018). \nhttps:\/\/doi.org\/10.1530\/eje-18-0318","journal-title":"Eur. J. Endocrinol."},{"key":"2034_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bone.2008.11.003","volume":"44","author":"GM Blake","year":"2009","unstructured":"G.M. Blake, J.F. Griffith, D.K. Yeung, P.C. Leung, I. Fogelman, Effect of increasing vertebral marrow fat content on BMD measurement, T-Score status and fracture risk prediction by DXA. Bone 44, 495\u2013501 (2009). \nhttps:\/\/doi.org\/10.1016\/j.bone.2008.11.003","journal-title":"Bone"},{"key":"2034_CR28","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Treatment of Cushing\u2019s Syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 100, 2807\u20132831 (2015). \nhttps:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2034_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","volume":"123","author":"G Mazziotti","year":"2010","unstructured":"G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877\u2013884 (2010). \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2010.02.028","journal-title":"Am. J. Med."},{"key":"2034_CR30","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.5650110716","volume":"11","author":"HK Genant","year":"1996","unstructured":"H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11, 984\u2013996 (1996). \nhttps:\/\/doi.org\/10.1002\/jbmr.5650110716","journal-title":"J. Bone Miner. Res."},{"key":"2034_CR31","doi-asserted-by":"publisher","first-page":"169526","DOI":"10.1155\/2013\/169526","volume":"2013","author":"JC Crane","year":"2013","unstructured":"J.C. Crane, M.P. Olson, S.J. Nelson, SIVIC: Open-Source, Standards-Based Software for DICOM MR Spectroscopy Workflows. Int. J. Biomed. Imaging 2013, 169526 (2013). \nhttps:\/\/doi.org\/10.1155\/2013\/169526","journal-title":"Int. J. Biomed. Imaging"},{"key":"2034_CR32","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/jmri.22489","volume":"33","author":"X Li","year":"2011","unstructured":"X. Li, D. Kuo, A.L. Schafer, A. Porzig, T.M. Link, D. Black, A.V. Schwartz, Quantification of vertebral bone marrow fat content using 3 Tesla MR spectroscopy: reproducibility, vertebral variation, and applications in osteoporosis. J. Magn. Reson. Imaging 33, 974\u2013979 (2011). \nhttps:\/\/doi.org\/10.1002\/jmri.22489","journal-title":"J. Magn. Reson. Imaging"},{"key":"2034_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jcb.240500411","volume":"50","author":"V Shalhoub","year":"1992","unstructured":"V. Shalhoub, D. Conlon, M. Tassinari, C. Quinn, N. Partridge, G.S. Stein, J.B. Lian, Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes. J. Cell. Biochem. 50, 425\u2013440 (1992). \nhttps:\/\/doi.org\/10.1002\/jcb.240500411","journal-title":"J. Cell. Biochem."},{"key":"2034_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0171-2985(11)80541-3","volume":"193","author":"A Wedel","year":"1995","unstructured":"A. Wedel, H.W. Ziegler-Heitbrock, The C\/EBP family of transcription factors. Immunobiology 193, 171\u2013185 (1995)","journal-title":"Immunobiology"},{"key":"2034_CR35","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1128\/MCB.16.8.4128","volume":"16","author":"Z Wu","year":"1996","unstructured":"Z. Wu, N.L. Bucher, S.R. Farmer, Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C\/EBPbeta, C\/EBPdelta, and glucocorticoids. Mol. Cell. Biol. 16, 4128\u20134136 (1996)","journal-title":"Mol. Cell. Biol."},{"key":"2034_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bbrc.2005.01.117","volume":"329","author":"K Ohnaka","year":"2005","unstructured":"K. Ohnaka, M. Tanabe, H. Kawate, H. Nawata, R. Takayanagi, Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem. Biophys. Res. Commun. 329, 177\u2013181 (2005). \nhttps:\/\/doi.org\/10.1016\/j.bbrc.2005.01.117","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2034_CR37","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1074\/jbc.M406294200","volume":"280","author":"E Smith","year":"2005","unstructured":"E. Smith, B. Frenkel, Glucocorticoids inhibit the transcriptional activity of LEF\/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and -independent manner. J. Biol. Chem. 280, 2388\u20132394 (2005). \nhttps:\/\/doi.org\/10.1074\/jbc.M406294200","journal-title":"J. Biol. Chem."},{"key":"2034_CR38","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1359\/jbmr.2000.15.7.1384","volume":"15","author":"A Oleksik","year":"2000","unstructured":"A. Oleksik, P. Lips, A. Dawson, M.E. Minshall, W. Shen, C. Cooper, J. Kanis, Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J. Bone Miner. Res. 15, 1384\u20131392 (2000). \nhttps:\/\/doi.org\/10.1359\/jbmr.2000.15.7.1384","journal-title":"J. Bone Miner. Res."},{"key":"2034_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"S. Vasikaran, R. Eastell, O. Bruyere, A.J. Foldes, P. Garnero, A. Griesmacher, M. McClung, H.A. Morris, S. Silverman, T. Trenti, D.A. Wahl, C. Cooper, J.A. Kanis, Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22, 391\u2013420 (2011). \nhttps:\/\/doi.org\/10.1007\/s00198-010-1501-1","journal-title":"Osteoporos. Int."},{"key":"2034_CR40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12020-016-0900-2","volume":"52","author":"SD Vasikaran","year":"2016","unstructured":"S.D. Vasikaran, S.A. Chubb, The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. Endocrine 52, 222\u2013225 (2016). \nhttps:\/\/doi.org\/10.1007\/s12020-016-0900-2","journal-title":"Endocrine"},{"key":"2034_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00223-004-0224-8","volume":"75","author":"V Sottile","year":"2004","unstructured":"V. Sottile, K. Seuwen, M. Kneissel, Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif. Tissue Int. 75, 329\u2013337 (2004). \nhttps:\/\/doi.org\/10.1007\/s00223-004-0224-8","journal-title":"Calcif. Tissue Int."},{"key":"2034_CR42","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bone.2017.01.013","volume":"97","author":"R Pedersini","year":"2017","unstructured":"R. Pedersini, S. Monteverdi, G. Mazziotti, V. Amoroso, E. Roca, F. Maffezzoni, L. Vassalli, F. Rodella, A.M. Formenti, S. Frara, R. Maroldi, A. Berruti, E. Simoncini, A. Giustina, Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study. Bone 97, 147\u2013152 (2017). \nhttps:\/\/doi.org\/10.1016\/j.bone.2017.01.013","journal-title":"Bone"},{"key":"2034_CR43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.bone.2009.06.006","volume":"45","author":"T Mancini","year":"2009","unstructured":"T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784\u2013788 (2009). \nhttps:\/\/doi.org\/10.1016\/j.bone.2009.06.006","journal-title":"Bone"},{"key":"2034_CR44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bone.2015.12.007","volume":"84","author":"G Mazziotti","year":"2016","unstructured":"G. Mazziotti, C. Dordoni, M. Doga, F. Galderisi, M. Venturini, P. Calzavara-Pinton, R. Maroldi, A. Giustina, M. Colombi, High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome. Bone 84, 88\u201392 (2016). \nhttps:\/\/doi.org\/10.1016\/j.bone.2015.12.007","journal-title":"Bone"},{"key":"2034_CR45","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40618-014-0126-1","volume":"37","author":"L Trementino","year":"2014","unstructured":"L. Trementino, L. Ceccoli, C. Concettoni, G. Marcelli, G. Michetti, M. Boscaro, G. Arnaldi, Fracture risk assessment before and after resolution of endogenous hypercortisolism: is the FRAX(R) algorithm useful? J. Endocrinol. Invest. 37, 957\u2013965 (2014). \nhttps:\/\/doi.org\/10.1007\/s40618-014-0126-1","journal-title":"J. Endocrinol. Invest."},{"key":"2034_CR46","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1210\/jcem.83.6.4880","volume":"83","author":"I Chiodini","year":"1998","unstructured":"I. Chiodini, V. Carnevale, M. Torlontano, S. Fusilli, G. Guglielmi, M. Pileri, S. Modoni, A. Di Giorgio, A. Liuzzi, S. Minisola, M. Cammisa, V. Trischitta, A. Scillitani, Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing\u2019s syndrome. J. Clin. Endocrinol. Metab. 83, 1863\u20131867 (1998). \nhttps:\/\/doi.org\/10.1210\/jcem.83.6.4880","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2034_CR47","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","volume":"78","author":"NC Harvey","year":"2015","unstructured":"N.C. Harvey, C.C. Gluer, N. Binkley, E.V. McCloskey, M.L. Brandi, C. Cooper, D. Kendler, O. Lamy, A. Laslop, B.M. Camargos, J.Y. Reginster, R. Rizzoli, J.A. Kanis, Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 78, 216\u2013224 (2015). \nhttps:\/\/doi.org\/10.1016\/j.bone.2015.05.016","journal-title":"Bone"},{"issue":"2","key":"2034_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/cen.13743","volume":"89","author":"Helene Vinolas","year":"2018","unstructured":"Vinolas, H., Grouthier, V., Mehsen-Cetre, N., Boisson, A., Winzenrieth, R., Schaeverbeke, T., Mesguich, C., Bordenave, L., Tabarin, A. Assessment of vertebral microarchitecture in overt and mild Cushing\u2019s syndrome using trabecular bone score. Clin. Endocrinol. (2018). \nhttps:\/\/doi.org\/10.1111\/cen.13743","journal-title":"Clinical Endocrinology"},{"key":"2034_CR49","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/bf03343737","volume":"23","author":"U Schafroth","year":"2000","unstructured":"U. Schafroth, K. Godang, T. Ueland, J.P. Berg, J. Bollerslev, Leptin levels in relation to body composition and insulin concentration in patients with endogenous Cushing\u2019s syndrome compared to controls matched for body mass index. J. Endocrinol. Invest. 23, 349\u2013355 (2000). \nhttps:\/\/doi.org\/10.1007\/bf03343737","journal-title":"J. Endocrinol. Invest."},{"key":"2034_CR50","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00198-006-0285-9","volume":"18","author":"W Shen","year":"2007","unstructured":"W. Shen, J. Chen, M. Punyanitya, S. Shapses, S. Heshka, S.B. Heymsfield, MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. Osteoporos. Int. 18, 641\u2013647 (2007). \nhttps:\/\/doi.org\/10.1007\/s00198-006-0285-9","journal-title":"Osteoporos. Int."},{"key":"2034_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1046\/j.0300-0664.2001.01454.doc.x","volume":"56","author":"C Di Somma","year":"2002","unstructured":"C. Di Somma, R. Pivonello, S. Loche, A. Faggiano, P. Marzullo, A. Di Sarno, M. Klain, M. Salvatore, G. Lombardi, A. Colao, Severe impairment of bone mass and turnover in Cushing\u2019s disease: comparison between childhood-onset and adulthood-onset disease. Clin. Endocrinol. 56, 153\u2013158 (2002)","journal-title":"Clin. Endocrinol."},{"key":"2034_CR52","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bone.2018.06.011","volume":"114","author":"MC Vlot","year":"2018","unstructured":"M.C. Vlot, M. den Heijer, R.T. de Jongh, M.G. Vervloet, W.F. Lems, R. de Jonge, B. Obermayer-Pietsch, A.C. Heijboer, Clinical utility of bone markers in various diseases. Bone 114, 215\u2013225 (2018). \nhttps:\/\/doi.org\/10.1016\/j.bone.2018.06.011","journal-title":"Bone"},{"key":"2034_CR53","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bone.2014.01.013","volume":"61","author":"A Bazzocchi","year":"2014","unstructured":"A. Bazzocchi, G. Garzillo, F. Fuzzi, D. Diano, U. Albisinni, E. Salizzoni, G. Battista, G. Guglielmi, Localizer sequences of magnetic resonance imaging accurately identify osteoporotic vertebral fractures. Bone 61, 158\u2013163 (2014). \nhttps:\/\/doi.org\/10.1016\/j.bone.2014.01.013","journal-title":"Bone"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02034-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-02034-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-02034-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T08:46:37Z","timestamp":1596271597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-02034-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2034"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-02034-4","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"17 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.M. received consultant fees by Ipsen and Novartis; A.L. received grants from Ipsen, Pfizer, Novartis and speaker honoraria from Ipsen and Pfizer; S.C. served in medical advisory boards of HRA. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}